# Lifyorli™ (relacorilant) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/relacorilant

> The PDUFA target action date for Lifyorli™ (relacorilant), sponsored by CORCEPT THERAPEUTICS INC (CORT), is December 17, 2026, for Cushing's syndrome - New Drug Application for relacorilant resubmitted. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Lifyorli™ (relacorilant) PDUFA date?

The PDUFA target action date for Lifyorli™ (relacorilant), sponsored by CORCEPT THERAPEUTICS INC (CORT), is December 17, 2026, for Cushing's syndrome - New Drug Application for relacorilant resubmitted. Status: scheduled. Press release filed with the SEC (EX-99): "•Relacorilant for patients with Cushing's syndrome - Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026" Last confirmed November 3, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/relacorilant)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-069494, https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/pdufa/relacorilant#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Lifyorli™ (relacorilant) |
| Codes | CORT125134 |
| Sponsor | CORCEPT THERAPEUTICS INC (CORT) https://sec-api.dev/companies/cort/catalysts |
| Indications | endogenous hypercortisolism, [platinum-resistant ovarian cancer](https://sec-api.dev/indications/platinum-resistant-ovarian-cancer), with cushing's syndrome, with platinum-resistant ovarian cancer in march 2026, hypercortisolism, cushing's syndrome - resubmitted new drug application prescription drug user fee act, Adenocarcinoma, [Ovarian Cancer](https://sec-api.dev/indications/ovarian-cancer) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 30, 2024: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: endogenous hypercortisolism.
- First seen 2025-02-26, last confirmed 2026-11-03.
- SEC Form 10-K (accession 0001628280-25-008167): "On December 30, 2024, we submitted to the United States Food and Drug Administration ("FDA") a New Drug Application ("NDA") for a proprietary cortisol modulator we have developed, relacorilant, that, like Korlym, modulates the effects of cortisol by binding at the GR, but has no affinity for the PR and so does not cause PR-related side effects." https://www.sec.gov/Archives/edgar/data/1088856/000162828025008167/cort-20241231.htm
- SEC Form 10-Q (accession 0001628280-26-069501): "In December 2024, we submitted a New Drug Application ("NDA") to the FDA seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-050613): "In December 2024, we submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/cort-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-028902): "In December 2024, we submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828026028902/cort-20260331.htm
- SEC Form 10-K (accession 0001628280-26-011091): "In December 2024, we submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm
- SEC Form 10-K (accession 0001628280-26-011091): "In December 2024, we submitted a NDA to the FDA seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-048841): "In December 2024, we submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828025048841/cort-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-037005): "In December 2024, we submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828025037005/cort-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-022173): "In December 2024, we submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828025022173/cort-20250331.htm
- SEC Form 10-K (accession 0001628280-25-008167): "In December 2024, we submitted an NDA to the FDA seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000162828025008167/cort-20241231.htm

### Apr 2025: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-04-30, last confirmed 2026-07-29.
- SEC Form 10-Q (accession 0001628280-26-050613): "In April 2025, we initiated BELLA, an open-label Phase 2 trial with three parts." https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/cort-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-028902): "In April 2025, we initiated a Phase 2 trial, BELLA, which has three parts." https://www.sec.gov/Archives/edgar/data/1088856/000162828026028902/cort-20260331.htm

### December 30, 2025: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: hypercortisolism.
- First seen 2025-05-05, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-048814): ""Our New Drug Application (NDA) for relacorilant in hypercortisolism has a Prescription Drug User Fee Act (PDUFA) date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-048814): "•FDA review of our relacorilant NDA continues, with a December 30, 2025 PDUFA date" https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-036999): "•Relacorilant for patients with hypercortisolism - FDA review of NDA continues, with Prescription Drug User Fee Act (PDUFA) date of December 30, 2025" https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/exhibit991pressrelease07-3.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-022167): "•Relacorilant for patients with hypercortisolism - U.S. Food and Drug Administration (FDA) accepted NDA for filing; Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025" https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/exhibit991pressrelease0505.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-158454): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025 for relacorilant as a treatment for patients with hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000119312525158454/d940113dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-199706): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of December 30, 2025 for relacorilant as a treatment for patients with hypercortisolism." https://www.sec.gov/Archives/edgar/data/1088856/000119312525199706/d947259dex991.htm
- SEC Form 10-Q (accession 0001628280-25-048841): "In March 2025, the FDA accepted the NDA for filing and assigned a Prescription Drug User Fee Act target action date ("PDUFA date") of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1088856/000162828025048841/cort-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-037005): "In March 2025, the FDA accepted the NDA for filing and assigned a Prescription Drug User Fee Act target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1088856/000162828025037005/cort-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-022173): "In March 2025, the FDA accepted the NDA for filing and assigned a Prescription Drug User Fee Act target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1088856/000162828025022173/cort-20250331.htm

### Mar 2026: FDA approval

- Status: completed, approved. Date confidence: month. Indication: with platinum-resistant ovarian cancer in March 2026.
- First seen 2026-04-30, last confirmed 2026-07-29.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-050607): "•FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer in March 2026" https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort072926ex991pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-028892): "•FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer in March 2026" https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/cort043026ex991pressrelease.htm

### Apr 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-11-03, last confirmed 2026-11-03.
- SEC Form 10-Q (accession 0001628280-26-069501): "Rather than requiring additional evidence, however, at the customary post-CRL meeting held in April 2026, the FDA asked for additional analyses of the data already submitted as part of our NDA - specifically, a global statistical test ("GST") of relacorilant's effect on three of the most common and serious symptoms of Cushing's syndrome - hypertension, hyperglycemia and excess body weight." https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm

### June 17, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2026-07-29, last confirmed 2026-11-03.
- SEC Form 10-Q (accession 0001628280-26-069501): "Based on the positive outcome of the requested analyses, we resubmitted our NDA to the FDA on June 17, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-069501): "Based on the outcome of those analyses, we resubmitted our NDA to the FDA on June 17, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-050613): "Based on the outcome of those analyses, we resubmitted our NDA to the FDA on June 17, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/cort-20260630.htm

### July 11, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: platinum-resistant ovarian cancer.
- First seen 2025-11-04, last confirmed 2026-02-24.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-011080): ""Our NDA for relacorilant in platinum-resistant ovarian cancer, which is now bolstered by the final overall survival results from our ROSELLA study, has a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-048814): "The PDUFA date for our NDA for relacorilant in platinum-resistant ovarian cancer is July 11, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-338184): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer." https://www.sec.gov/Archives/edgar/data/1088856/000119312525338184/d50993dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-018704): "Relacorilant's New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026" https://www.sec.gov/Archives/edgar/data/1088856/000119312526018704/d96058dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-018704): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer." https://www.sec.gov/Archives/edgar/data/1088856/000119312526018704/d96058dex991.htm
- SEC Form 10-K (accession 0001628280-26-011091): "In September 2025, the FDA accepted our NDA for filing and assigned a Prescription Drug User Fee Act ("PDUFA") date of July 11, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm
- SEC Form 10-K (accession 0001628280-26-011091): "In September 2025, the FDA accepted our NDA for filing and assigned a PDUFA date of July 11, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-048841): "In September 2025, the FDA accepted our NDA for filing and assigned a PDUFA date of July 11, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828025048841/cort-20250930.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Cushing Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03604198 (Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." https://clinicaltrials.gov/study/NCT03604198

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Cushing Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03604198 (Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." https://clinicaltrials.gov/study/NCT03604198

### December 17, 2026: NDA/BLA submission

- Status: scheduled. Date confidence: exact. Indication: with Cushing's syndrome.
- First seen 2026-07-29, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-069494): "resubmission of our NDA for relacorilant for the treatment of patients with Cushing's syndrome and our expectation that the FDA will issue a decision on this NDA by December 17, 2026" https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-050607): "resubmission of our NDA for relacorilant for the treatment of patients with Cushing's syndrome and our expectation that the FDA will issue a decision on this NDA by December 17, 2026" https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort072926ex991pressrelease.htm

### December 17, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: Cushing's syndrome - New Drug Application for relacorilant resubmitted.
- First seen 2026-07-29, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-069494): "•Relacorilant for patients with Cushing's syndrome - Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026" https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-050607): "•Relacorilant for patients with Cushing's syndrome - New Drug Application for relacorilant resubmitted with a Prescription Drug User Fee Act (PDUFA) date of December 17, 2026" https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort072926ex991pressrelease.htm
- SEC Form 10-Q (accession 0001628280-26-069501): "The FDA has assigned a Prescription Drug User Fee Act target date of December 17, 2026 to complete its review." https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-050613): "The FDA has assigned a Prescription Drug User Fee Act target date of December 17, 2026 to complete its review." https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/cort-20260630.htm

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Adenocarcinoma; Carcinoma, Pancreatic Ductal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07259317 (Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Corcept Therapeutics." https://clinicaltrials.gov/study/NCT07259317

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Adenocarcinoma; Carcinoma, Pancreatic Ductal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07259317 (Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Corcept Therapeutics." https://clinicaltrials.gov/study/NCT07259317

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06906341 (Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." https://clinicaltrials.gov/study/NCT06906341

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06906341 (Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." https://clinicaltrials.gov/study/NCT06906341

## Same indication

- [Corcept](https://sec-api.dev/pdufa/corcept) (CORT)
- [INCB123667](https://sec-api.dev/pdufa/incb123667) (INCY)
- [Luveltamab tazevibulin](https://sec-api.dev/pdufa/luveltamab-tazevibulin) (STRO)
- [Mirvetuximab soravtansine](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) (ABBV)
- [Mirvetuximab soravtansine plus bevacizumab](https://sec-api.dev/pdufa/mirvetuximab-soravtansine-plus-bevacizumab) (ABBV)
- [LYNPARZA® (olaparib)](https://sec-api.dev/pdufa/olaparib) (AZN)
- [TAXOL® (paclitaxel)](https://sec-api.dev/pdufa/paclitaxel) (TEVA)
- [Pamiparib capsule](https://sec-api.dev/pdufa/pamiparib) (ONC)
- [REGN10597](https://sec-api.dev/pdufa/regn10597) (REGN)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Rinatabart](https://sec-api.dev/pdufa/rinatabart) (GMAB)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [Vudalimab](https://sec-api.dev/pdufa/vudalimab) (XNCR)

Calendar months: [December 2025](https://sec-api.dev/fda-calendar/2025-12), [July 2026](https://sec-api.dev/fda-calendar/2026-07), [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/relacorilant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lifyorli™ (relacorilant) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/relacorilant

```bibtex
@misc{secapidev_pdufa_relacorilant_20261116,
  title        = {Lifyorli™ (relacorilant) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/relacorilant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_relacorilant_20261116","title":"Lifyorli™ (relacorilant) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/relacorilant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
